Lawmakers Step Up to the Plate on Healthcare
As Congress continues to debate the best fixes for our healthcare system, our representatives in Washington have an opportunity to...
The Trump Administration’s Drug Pricing Plan: Three Wishes For Consumers
This week President Trump will unveil his plan to help bring down the cost of prescription drugs, helping fulfill his...
CASE Op-Ed: PBMs are Pocketing Patient Assistance Money, Increasing Costs for Consumers
Matthew Kandrach – President, CASE April 3rd, 2018 – https://bit.ly/2q4a2UO Pharmacy Benefit Managers (PBMs) — health insurance middle-men wedged between plan...
PBMs Get Aggressive to Keep Their Drug Profits Secret from Consumers
If the makers of Coke or KFC’s famous fried chicken ever fear for keeping their recipes private and confidential, they...
Dunkin’ the Donut Hole – Budget Plan Proposal Would Sink Medicare Part D in Higher Costs
The infamous Medicare Part D ‘donut hole,’ which leaves seniors with a coverage gap for prescription drugs, has vexed Washington...
CASE Op-Ed: Transparency Is Key to Lower Medicare Part D Costs
http://bit.ly/2EsfFSE Matthew Kandrach, CASE President Government programs don’t have a great track record of coming in under budget, but Medicare...
CASE Op-ed: PBM Reforms Would Save Consumers Millions on Prescription Drugs
Read full article here: by CASE President Matthew Kandrach Pharmacy Benefit Managers (PBMs), the goliath health insurance middle-men wedged between...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/